GSK plc (GSK) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $59.18. It has a SharesGrow Score of 64/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of GSK = $145.21 (+145.4% from the current price, the stock appears undervalued). Analyst consensus target is GSK = $53 (-10.4% upside).
Valuation: GSK trades at a trailing Price-to-Earnings (P/E) of 15 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.49.
Financials: revenue is $32.0B, +2.9%/yr average growth. Net income is $5.6B, growing at +23.2%/yr. Net profit margin is 17.5% (healthy). Gross margin is 72.5% (+5.1 pp trend).
Balance sheet: total debt is $17.7B against $16.3B equity (Debt-to-Equity (D/E) ratio 1.08, moderate). Current ratio is 0.82 (tight liquidity). Debt-to-assets is 29%. Total assets: $61.0B.
Analyst outlook: 9 / 29 analysts rate GSK as buy (31%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 49/100 (Partial), Growth 73/100 (Pass), Past 100/100 (Pass), Health 50/100 (Partial), Moat 90/100 (Pass), Future 16/100 (Fail), Income 70/100 (Pass).
